MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis
Journal of Investigative Dermatology · 2026
DOI: 10.1016/j.jid.2026.04.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026. Verfasst von Joshua Wollam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Escient Pharmaceuticals (a subsidiary of Incyte Corporation), San Diego, California, USA. Electronic address: joshuapwollam@gmail.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Receptors, G-Protein-Coupled, Receptors, Neuropeptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Incyte.
Abstract (Originalsprache)
The Mas-related G-protein-coupled receptor X2 is a promiscuous receptor expressed on mast cells that mediates IgE-independent mast cell activation and degranulation in response to a variety of diverse agonists and has been implicated in numerous inflammatory conditions, including atopic dermatitis (AD). We investigated whether the small-molecule Mas-related G-protein-coupled receptor X2 antagonist INCB000262 improves disease phenotype in the house dust mite + Staphylococcus aureus enterotoxin type B (HDM+SEB) mouse model of AD and further characterized mast cell-mediated aspects of disease. Mas-related G-protein-coupled receptor X2 knock-in mice were sensitized to HDM+SEB and orally dosed once daily with either vehicle or INCB000262 for 4 weeks, and efficacy and skin transcriptional changes were evaluated. INCB000262 attenuated HDM+SEB-induced AD in vivo, with improvements observed in skin thickness, transepidermal water loss, tissue weight, and overall clinical score. In addition, transcriptome changes induced by HDM+SEB exhibited a mast cell activation signature consistent with human AD lesional skin, which was attenuated by antagonist treatment. Overall, INCB000262, a Mas-related G-protein-coupled receptor X2 antagonist, attenuated HDM+SEB-induced AD disease phenotypes and mast cell-associated transcriptional changes, supporting further evaluation of INCB000262 as an oral treatment for AD and other mast cell-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Escient Pharmaceuticals (a subsidiary of Incyte Corporation), San Diego, California, USA. Electronic address: joshuapwollam@gmail.com.
- Escient Pharmaceuticals (a subsidiary of Incyte Corporation), San Diego, California, USA.
Förderung
- Incyte
Zitieren
APA
Wollam, J., Solomon, M., Villescaz, C., Srinivasan, S., Charlot, B., Vest, A., Napora, J., Cavarlez, C., Vasquez, A., Dvorak, L., & Viswanath, V. (2026). MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.04.021
Vancouver
Wollam J, Solomon M, Villescaz C, Srinivasan S, Charlot B, Vest A, et al. MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis. Journal of Investigative Dermatology. 2026. doi:10.1016/j.jid.2026.04.021
BibTeX
@article{Wollam2026,
author = {Wollam, Joshua and Solomon, Michelle and Villescaz, Christiane and Srinivasan, Swetha and Charlot, Brittney and Vest, Alan and Napora, Jim and Cavarlez, Christine and Vasquez, Alexis and Dvorak, Lisa and Viswanath, Veena},
title = {MRGPRX2 antagonist treatment prevents inflammation and disease in a mouse model of atopic dermatitis},
journal = {Journal of Investigative Dermatology},
year = {2026},
doi = {10.1016/j.jid.2026.04.021}
}
EUVIMED